CytomX - ein bahnbrechender Ansatz in der Tumortherapie (Seite 35)
eröffnet am 01.07.16 16:03:16 von
neuester Beitrag 27.01.24 11:32:06 von
neuester Beitrag 27.01.24 11:32:06 von
Beiträge: 1.459
ID: 1.234.534
ID: 1.234.534
Aufrufe heute: 0
Gesamt: 163.656
Gesamt: 163.656
Aktive User: 0
ISIN: US23284F1057 · WKN: A14158 · Symbol: CTMX
1,6300
USD
+1,24 %
+0,0200 USD
Letzter Kurs 30.04.24 Nasdaq
Neuigkeiten
08.04.24 · globenewswire  |
03.04.24 · globenewswire |
21.03.24 · globenewswire |
18.03.24 · globenewswire |
12.03.24 · wO Chartvergleich |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5888 | +476,69 | |
| 2,1100 | +54,58 | |
| 7,0200 | +39,84 | |
| 1,9000 | +33,80 | |
| 1,1750 | +25,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,0700 | -20,08 | |
| 27,53 | -22,47 | |
| 5,5700 | -23,49 | |
| 3,5000 | -26,24 | |
| 0,5103 | -40,66 |
Beitrag zu dieser Diskussion schreiben
Feedback
Credit Suisse
CytomX Therapeutics (NASDAQ:CTMX) downgraded to Neutral with an $8 (34% upside) price target at Wedbush. Shares down a fraction premarket.
CytomX Therapeutics (NASDAQ:CTMX) downgraded to Neutral with an $8 (34% upside) price target at Wedbush. Shares down a fraction premarket.
Die Zahlen sind raus.
http://ir.cytomx.com/news-releases/news-release-details/cyto…
CytomX Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update
November 7, 2019 at 4:09 PM EST
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform, today reported third quarter 2019 financial results.
As of September 30, 2019, CytomX had cash, cash equivalents and short-term investments of $325.7 million.
“The CytomX clinical pipeline made excellent progress in Q3 as we continued to advance multiple Probody therapeutic programs across the portfolio,” said Sean McCarthy, D.Phil., president, chief executive officer and chairman of CytomX Therapeutics. “The initiation of a Phase 2 trial of our anti-PD-L1 Probody CX-072 in combination with ipilimumab in patients with relapsed refractory melanoma marks our ongoing evolution into a product-focused company seeking to realize the full potential of our novel technology platform. Our first in class Probody Drug Conjugate programs, CX-2009 and CX-2029, also continued to move forward and our pipeline overall is positioned for significant data updates in 2020.”
Business Highlights and Recent Developments
CX-072 Anti-PD-L1 Probody Therapeutic Clinical Program
- In October, CytomX announced the initiation of the PROCLAIM (Probody Clinical Assessment In Man) CX-072-002 Phase 2 study evaluating the efficacy and tolerability of the anti-PD-L1 Probody CX-072, in combination with the anti-CTLA-4 antibody, ipilimumab, in patients with relapsed or refractory melanoma. The study utilizes a Simon Two-Stage design with approximately 40 patients being enrolled into Stage 1. CytomX anticipates initial data from Stage 1 in 2020. Additional information on this trial is available at ClinicalTrials.gov using the identifier NCT03993379.
- The Company also announced in October updated clinical data from the Phase 1 PROCLAIM-CX-072-001 dose-finding study of CX-072 in combination with ipilimumab. With enrollment complete, 27 evaluable patients had received ipilimumab (3, 6 or 10 mg/kg) combined with CX-072 (0.3, 1, 3 or 10 mg/kg), with the study achieving a disease control rate (stable disease or better) of 37%. 5 patients achieved confirmed objective responses by RECIST v1.1, including one complete response, for an overall response rate (ORR) of 19% in this heavily pretreated patient population. The median duration of response was 14.6 months (1.9 - 21.2 months) with 4 of the 5 responders still on treatment as of the latest data snapshot. Of the 27 patients treated across all doses, Grade 3/4 treatment related adverse events (TRAEs) were reported in 9 (33%) patients. Grade 3/4 immune-related adverse events (irAEs) were reported in 3 (15%) patients.
- Enrollment within the monotherapy cohorts of the PROCLAIM-CX-072-001 study is complete with evaluation of the activity and tolerability of CX-072 monotherapy continuing with ongoing treatment in select cohorts. Additional information on this trial is available at ClinicalTrials.gov using the identifier NCT03013491.
CX-2009 Anti-CD166 Probody Drug Conjugate Clinical Program
CytomX anticipates announcing next steps for the PROCLAIM-CX-2009 clinical program by the end of 2019.
BMS-986249 Anti-CTLA-4 Probody Therapeutic Clinical Program
- Bristol-Myers Squibb (BMS) is conducting a Phase 1/2a dose escalation clinical study evaluating BMS-986249 alone and in combination with OPDIVO® (nivolumab) in advanced solid tumors.
- BMS is preparing to initiate the Phase 2 portion of this clinical trial, upon which CytomX is entitled to a $10 million milestone payment. Additional information on this trial is available at ClinicalTrials.gov using the Identifier NCT03369223.
CX-2029 Anti-CD71 Probody Drug Conjugate Clinical Program
- CytomX continued enrollment of patients in the PROCLAIM-CX-2029 Phase 1/2 study, which is partnered with AbbVie, evaluating CX-2029 as monotherapy in patients with solid tumors or lymphomas. Additional information on this trial is available at ClinicalTrials.gov using the Identifier NCT003543813.
Additional Corporate Highlights
- In October, the Company announced the appointment of Amy C. Peterson, M.D., as executive vice president and chief development officer. In this new role, Dr. Peterson will have oversight of a multi-disciplinary team focused on advancing all aspects of CytomX’s clinical development activities.
- In July, the Company announced that its partner AbbVie selected a second target under the companies’ 2016 Discovery Collaboration and Licensing Agreement to discover and develop Probody drug conjugates. The target selection triggered a $10 million payment to CytomX from AbbVie.
Third Quarter 2019 Financial Results
Cash, cash equivalents and short-term investments totaled $325.7 million as of September 30, 2019, compared to $436.1 million as of December 31, 2018.
Revenue was $10.7 million for the three months ended September 30, 2019, compared to $12.5 million for the three months ended September 30, 2018. The decrease in revenue of $1.8 million for the three months ended September 30, 2019 compared to the corresponding period in 2018 was primarily due to a $1.7 million decrease in revenue recognition under the CD71 Agreement with AbbVie due to ongoing dose escalation.
Research and development expenses increased $0.4 million during the three months ended September 30, 2019 compared to the corresponding period in 2018. The increase was attributable to an increase of $1.3 million in personnel-related expenses primarily due to an increase in headcount; an increase of $0.7 million in consulting expenses resulting from increased clinical trial activities and an increase of $0.8 million in the allocation of information technology and facilities related expenses driven partly from an increase in headcount; which amounts were offset by a decrease of $2.4 million in laboratory contracts and services and laboratory supplies as a result of timing of manufacturing activities as well as reduced costs relating to CX-188 which is not presently being advanced.
General and administrative expenses increased by $0.3 million during the three months ended September 30, 2019 compared to the corresponding period in 2018. The increase was attributable to an increase of $0.4 million in consulting expenses primarily related to IT, software implementation and finance services; an increase of $0.5 million in dues and subscriptions primarily related to software and other IT services; an increase of $0.2 million in building maintenance charges; which amounts were partially offset by a decrease of $0.8 million of information technology and facilities-related expenses allocated to the general and administrative functions.
--------------------------------------------
Dazu gibs noch das Transcript des Earnings Calls (kostenloser Login erforderlich)
https://seekingalpha.com/article/4304096-cytomx-therapeutics…
--------------------------------------------
Hat irgendwer eine Meinung zu den Programmen? Joschka fehlt hier echt. Wie toll wäre mal eine fundierte Meinung.
Cytomx scheint weiter optimistisch, aber der Markt teilt diese Meinung irgendwie nicht. Es wurde auch nach einer Verpartnerung von CX-072 gefragt. Die Antwort war, dass sie dafür zu gegebener Zeit offen sind. Mir wäre sofort am liebsten. Das Risiko sollte mal ein wenig gesenkt werden. Da wäre mir weniger Upsidepotential recht.
http://ir.cytomx.com/news-releases/news-release-details/cyto…
CytomX Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update
November 7, 2019 at 4:09 PM EST
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody therapeutic technology platform, today reported third quarter 2019 financial results.
As of September 30, 2019, CytomX had cash, cash equivalents and short-term investments of $325.7 million.
“The CytomX clinical pipeline made excellent progress in Q3 as we continued to advance multiple Probody therapeutic programs across the portfolio,” said Sean McCarthy, D.Phil., president, chief executive officer and chairman of CytomX Therapeutics. “The initiation of a Phase 2 trial of our anti-PD-L1 Probody CX-072 in combination with ipilimumab in patients with relapsed refractory melanoma marks our ongoing evolution into a product-focused company seeking to realize the full potential of our novel technology platform. Our first in class Probody Drug Conjugate programs, CX-2009 and CX-2029, also continued to move forward and our pipeline overall is positioned for significant data updates in 2020.”
Business Highlights and Recent Developments
CX-072 Anti-PD-L1 Probody Therapeutic Clinical Program
- In October, CytomX announced the initiation of the PROCLAIM (Probody Clinical Assessment In Man) CX-072-002 Phase 2 study evaluating the efficacy and tolerability of the anti-PD-L1 Probody CX-072, in combination with the anti-CTLA-4 antibody, ipilimumab, in patients with relapsed or refractory melanoma. The study utilizes a Simon Two-Stage design with approximately 40 patients being enrolled into Stage 1. CytomX anticipates initial data from Stage 1 in 2020. Additional information on this trial is available at ClinicalTrials.gov using the identifier NCT03993379.
- The Company also announced in October updated clinical data from the Phase 1 PROCLAIM-CX-072-001 dose-finding study of CX-072 in combination with ipilimumab. With enrollment complete, 27 evaluable patients had received ipilimumab (3, 6 or 10 mg/kg) combined with CX-072 (0.3, 1, 3 or 10 mg/kg), with the study achieving a disease control rate (stable disease or better) of 37%. 5 patients achieved confirmed objective responses by RECIST v1.1, including one complete response, for an overall response rate (ORR) of 19% in this heavily pretreated patient population. The median duration of response was 14.6 months (1.9 - 21.2 months) with 4 of the 5 responders still on treatment as of the latest data snapshot. Of the 27 patients treated across all doses, Grade 3/4 treatment related adverse events (TRAEs) were reported in 9 (33%) patients. Grade 3/4 immune-related adverse events (irAEs) were reported in 3 (15%) patients.
- Enrollment within the monotherapy cohorts of the PROCLAIM-CX-072-001 study is complete with evaluation of the activity and tolerability of CX-072 monotherapy continuing with ongoing treatment in select cohorts. Additional information on this trial is available at ClinicalTrials.gov using the identifier NCT03013491.
CX-2009 Anti-CD166 Probody Drug Conjugate Clinical Program
CytomX anticipates announcing next steps for the PROCLAIM-CX-2009 clinical program by the end of 2019.
BMS-986249 Anti-CTLA-4 Probody Therapeutic Clinical Program
- Bristol-Myers Squibb (BMS) is conducting a Phase 1/2a dose escalation clinical study evaluating BMS-986249 alone and in combination with OPDIVO® (nivolumab) in advanced solid tumors.
- BMS is preparing to initiate the Phase 2 portion of this clinical trial, upon which CytomX is entitled to a $10 million milestone payment. Additional information on this trial is available at ClinicalTrials.gov using the Identifier NCT03369223.
CX-2029 Anti-CD71 Probody Drug Conjugate Clinical Program
- CytomX continued enrollment of patients in the PROCLAIM-CX-2029 Phase 1/2 study, which is partnered with AbbVie, evaluating CX-2029 as monotherapy in patients with solid tumors or lymphomas. Additional information on this trial is available at ClinicalTrials.gov using the Identifier NCT003543813.
Additional Corporate Highlights
- In October, the Company announced the appointment of Amy C. Peterson, M.D., as executive vice president and chief development officer. In this new role, Dr. Peterson will have oversight of a multi-disciplinary team focused on advancing all aspects of CytomX’s clinical development activities.
- In July, the Company announced that its partner AbbVie selected a second target under the companies’ 2016 Discovery Collaboration and Licensing Agreement to discover and develop Probody drug conjugates. The target selection triggered a $10 million payment to CytomX from AbbVie.
Third Quarter 2019 Financial Results
Cash, cash equivalents and short-term investments totaled $325.7 million as of September 30, 2019, compared to $436.1 million as of December 31, 2018.
Revenue was $10.7 million for the three months ended September 30, 2019, compared to $12.5 million for the three months ended September 30, 2018. The decrease in revenue of $1.8 million for the three months ended September 30, 2019 compared to the corresponding period in 2018 was primarily due to a $1.7 million decrease in revenue recognition under the CD71 Agreement with AbbVie due to ongoing dose escalation.
Research and development expenses increased $0.4 million during the three months ended September 30, 2019 compared to the corresponding period in 2018. The increase was attributable to an increase of $1.3 million in personnel-related expenses primarily due to an increase in headcount; an increase of $0.7 million in consulting expenses resulting from increased clinical trial activities and an increase of $0.8 million in the allocation of information technology and facilities related expenses driven partly from an increase in headcount; which amounts were offset by a decrease of $2.4 million in laboratory contracts and services and laboratory supplies as a result of timing of manufacturing activities as well as reduced costs relating to CX-188 which is not presently being advanced.
General and administrative expenses increased by $0.3 million during the three months ended September 30, 2019 compared to the corresponding period in 2018. The increase was attributable to an increase of $0.4 million in consulting expenses primarily related to IT, software implementation and finance services; an increase of $0.5 million in dues and subscriptions primarily related to software and other IT services; an increase of $0.2 million in building maintenance charges; which amounts were partially offset by a decrease of $0.8 million of information technology and facilities-related expenses allocated to the general and administrative functions.
--------------------------------------------
Dazu gibs noch das Transcript des Earnings Calls (kostenloser Login erforderlich)
https://seekingalpha.com/article/4304096-cytomx-therapeutics…
--------------------------------------------
Hat irgendwer eine Meinung zu den Programmen? Joschka fehlt hier echt. Wie toll wäre mal eine fundierte Meinung.
Cytomx scheint weiter optimistisch, aber der Markt teilt diese Meinung irgendwie nicht. Es wurde auch nach einer Verpartnerung von CX-072 gefragt. Die Antwort war, dass sie dafür zu gegebener Zeit offen sind. Mir wäre sofort am liebsten. Das Risiko sollte mal ein wenig gesenkt werden. Da wäre mir weniger Upsidepotential recht.
Antwort auf Beitrag Nr.: 61.759.844 von riverstar_de am 24.10.19 19:59:46Es wird munter der Rest des Cashs verbrannt. Vermutlich bald insolvent der Laden. , zumindest nach Ansicht der Börse. Von der Führungsriege hört man auch nix mehr.
Antwort auf Beitrag Nr.: 61.756.931 von Jerry_Maguire am 24.10.19 14:13:29
mein iPad meldet mir immer öfter: CTMX reached a new All time Low. LOL. Einziges Trauerspiel.
Zitat von Jerry_Maguire: Cytom X bringt Q3 Bericht am 7.11.19 5:00 pm ET (22:00 MEZ). Login für den Webcast 15 min vor Beginn.
http://ir.cytomx.com/news-releases/news-release-details/cyto…
Gruß
JM
mein iPad meldet mir immer öfter: CTMX reached a new All time Low. LOL. Einziges Trauerspiel.
Cytom X bringt Q3 Bericht am 7.11.19 5:00 pm ET (22:00 MEZ). Login für den Webcast 15 min vor Beginn.
http://ir.cytomx.com/news-releases/news-release-details/cyto…
Gruß
JM
http://ir.cytomx.com/news-releases/news-release-details/cyto…
Gruß
JM
Trading Spotlight
Antwort auf Beitrag Nr.: 61.742.833 von Jerry_Maguire am 22.10.19 12:59:06Muss much korrigieren. Im entsprechenden SEC filing ist zu lesen, dass es für Peterson eine automatisierte Ausschüttung in 25% Chargen zum jeweils 15.10. eines Jahres beginnend ab 2020 kommen wird.
Gruß
JM
Gruß
JM
Der neuen CDO Amy C Peterson wurden Aktionoptionen über 400.000 Aktien zum Wert von 7,16 USD (Notierung zum 15.10.) als Antrittsprämie zugesichert. Man kann ja von Insiderkäufen halten und darüber spekulieren wie man will. Einigermaßen interessant könnte es trotzdem werden, wann sie diese einlöst. Als CDO dürfte sie tiefe Einblicke in den Stand der Entwicklung haben und mit ihrer Erfahrung auch den kommerziellen Erfolg besser einschätzen können. Daher würde ich dem dann hohe Bedeutung zuordnen.
http://ir.cytomx.com/news-releases/news-release-details/cyto…
Gruß
JM
http://ir.cytomx.com/news-releases/news-release-details/cyto…
Gruß
JM
Antwort auf Beitrag Nr.: 61.716.536 von Jerry_Maguire am 18.10.19 10:28:57
Jo, war mir schon klar, dass da so ein Schlaumeier mit dem Kommentar kommen wird. Ich versuche, so transparent wie möglich zu sein mit dem, was ich im Forum schreibe. Dass ich hier mit dem Trading Gedanken einsteige, habe ich in meinem Posting vom 7.9.19 klar und wortwörtlich so dargelegt. Ziel war eigentlich der Durchbruch durch den 10 USD Widerstand bis nach 11-13 USD, wie ebenso explizit beschrieben im entsprechenden Posting.
Leider, oder eben in dem Falle zum Glück, musste ich nach ein paar Wochen mangels freiem Kapital Prioritäten setzen. Da der Kurs bei 10USD abgeprallt war aber trotzdem noch im Plus war, hat es sich angeboten, diese Position aufzulösen. Normalerweise hätte ich das zeitnah beschrieben, was ich aber leider verpasst habe und erst diese Woche realisiert hatte. Hätte nun auch einfach meine Klappe halten können, so hätte ich mir deinen sinnlosen Kommentar erspart, aber was solls ... die einen schätzen Transparenz, die anderen kommen halt nur ins Forum um ihren Frust abzulassen.
Zitat von Jerry_Maguire: Na solche Beiträge sind ja immer die Besten. Rein bei ... und raus bei ... vor x Wochen. Glück gehabt... Achso, ist klar. Trading bei einem Wert mit so wenig Handelsvolumen, da braucht man nicht mehr weiter lesen.
Jo, war mir schon klar, dass da so ein Schlaumeier mit dem Kommentar kommen wird. Ich versuche, so transparent wie möglich zu sein mit dem, was ich im Forum schreibe. Dass ich hier mit dem Trading Gedanken einsteige, habe ich in meinem Posting vom 7.9.19 klar und wortwörtlich so dargelegt. Ziel war eigentlich der Durchbruch durch den 10 USD Widerstand bis nach 11-13 USD, wie ebenso explizit beschrieben im entsprechenden Posting.
Leider, oder eben in dem Falle zum Glück, musste ich nach ein paar Wochen mangels freiem Kapital Prioritäten setzen. Da der Kurs bei 10USD abgeprallt war aber trotzdem noch im Plus war, hat es sich angeboten, diese Position aufzulösen. Normalerweise hätte ich das zeitnah beschrieben, was ich aber leider verpasst habe und erst diese Woche realisiert hatte. Hätte nun auch einfach meine Klappe halten können, so hätte ich mir deinen sinnlosen Kommentar erspart, aber was solls ... die einen schätzen Transparenz, die anderen kommen halt nur ins Forum um ihren Frust abzulassen.
Antwort auf Beitrag Nr.: 61.694.938 von wandstrasse-ch am 15.10.19 13:48:10Na solche Beiträge sind ja immer die Besten. Rein bei ... und raus bei ... vor x Wochen. Glück gehabt... Achso, ist klar. Trading bei einem Wert mit so wenig Handelsvolumen, da braucht man nicht mehr weiter lesen.
Etwas Insight zum neuen Personal:
https://www.globenewswire.com/news-release/2019/10/14/192913…
Immerhin hat John McCarthy verstanden, das CTX Investoren aetwas Bewegung hin zum nächsten Level, d.h. Marktzulassung sehen wollen. Bisher hatte man ja den Eindruck, CTX forschen lieber in ihren Laboren still und leise vor sich hin.
Gruß
JM
Etwas Insight zum neuen Personal:
https://www.globenewswire.com/news-release/2019/10/14/192913…
Immerhin hat John McCarthy verstanden, das CTX Investoren aetwas Bewegung hin zum nächsten Level, d.h. Marktzulassung sehen wollen. Bisher hatte man ja den Eindruck, CTX forschen lieber in ihren Laboren still und leise vor sich hin.
Gruß
JM
Bin bei ca. 9.50 USD wieder raus, nachdem der Kurs bei 10 USD abgeprallt ist. Allerdings nicht in "weiser Voraussicht" des Absturzes sondern weil ich Kapital für ein anderes Investment gebraucht habe und Prioritäten setzen musste. War somit auch Glück dabei für mich. Sorry, dass ich das nicht früher mitgeteilt hatte.
Bei den aktuellen rund 7 USD bietet sich aus meiner Sicht aber wieder eine neue Trading Chance. Gab auch News bez. einem neuen Chief Development Officer und weiterer Newsflow kann erwartet werden:
https://seekingalpha.com/pr/17661085-cytomx-therapeutics-ann…
Werde selbst aber momentan nicht mehr wieder einsteigen, da ich mich aktuell auf andere Sachen fokussiere. Viel Erfolg allerseits.
Bei den aktuellen rund 7 USD bietet sich aus meiner Sicht aber wieder eine neue Trading Chance. Gab auch News bez. einem neuen Chief Development Officer und weiterer Newsflow kann erwartet werden:
https://seekingalpha.com/pr/17661085-cytomx-therapeutics-ann…
Werde selbst aber momentan nicht mehr wieder einsteigen, da ich mich aktuell auf andere Sachen fokussiere. Viel Erfolg allerseits.
Durchsuchen
CytomX - ein bahnbrechender Ansatz in der Tumortherapie
